A bullish thesis on PROCEPT BioRobotics Corporation argues the stock is undervalued relative to Intuitive Surgical's historical valuation at a similar revenue stage. PROCEPT BioRobotics has quadrupled revenues since 2022 and currently trades at approximately 4.5 times sales, while Intuitive Surgical traded between 9 and 18 times sales when it crossed a roughly $300 million revenue threshold in mid-2006. The thesis suggests that if PROCEPT BioRobotics continues to replicate Intuitive Surgical's trajectory, multiple expansion and revenue growth could drive roughly 150% equity upside over three years. Near-term sentiment is mixed after management guided revenue slightly below expectations, though still reflecting about 30% year-over-year growth, while 2027 revenue guidance points to a step-change acceleration that remains underappreciated by analysts. Even in a conservative scenario, the business is expected to sustain approximately 25% annual revenue growth, limiting downside risk given the already compressed valuation multiple.
Procept Biorobotics CorpBullish thesis argues stock is undervalued relative to Intuitive Surgical's historical multiples, with potential for 150% upside.
Intuitive Surgical Inc